source
- Patient dies after receiving Bristol Myers experimental autoimmune CAR-T therapy zola-celA participant in Bristol Myers Squibb’s multiple sclerosis trial died 44 days after being infused with the experimental cell therapy known as zola-cel. The company disclosed that the patient develo…
- Overlooked drugs can gain value when markets evolve, says Azurity CEORon Scarboro, chief executive of Azurity Pharmaceuticals, wrote about how medicines that seemed unsuccessful can become valuable when market conditions change. He argues that the industry often co…